arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ABEONA THERAPEUTICS INC.

ABEO
$7.24 ▲ +0.35 (+5.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
64
Health
Fair
Bullish
auto_awesome

Analytical Summary

ABEONA THERAPEUTICS INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $409.9M
Dividend Yield
Revenue Growth None
Op. Margin -264.1%
ROIC -14.1%
FCF / Share $-0.37
Trailing P/E
Price / Book 2.8x
FCF Yield
Debt / Equity 0.12
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.72M
↑ +60.9%
Net Income Profit after all expenses
$-17.07M
↓ -41.9%
Operating Margin Operating profit as % of sales
-264.1%
↑ +37.5%
FCF / Share Free cash flow per share
$-0.37
↑ +7.9%
Long-Term Debt Long-term obligations
$18.09M
↓ -9.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
96
Financial Health
51
Cash Quality
9

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters